Adrafinil‐induced orofacial dyskinesia

  title={Adrafinil‐induced orofacial dyskinesia},
  author={St{\'e}phane Thobois and Jing Xie and H{\'e}l{\`e}ne Mollion and Isabelle B{\'e}natru and Emmanuel Broussolle},
  journal={Movement Disorders},
We describe the first case of orofacial abnormal movements induced by adrafinil, a vigilance promoting agent of the same pharmacological class as modafinil. The dyskinesias did not spontaneously recover despite adrafinil withdrawal for a 4‐month period. They were secondly dramatically improved by tetrabenazine, a presynaptic dopaminergic depleting drug which was introduced after the 4‐month adrafinil‐free period. © 2004 Movement Disorder Society 
Modafinil-induced orofacial dyskinesia in an elderly patient with refractory bipolar depression.
The timeline outlined a causal relationship between modafinil and the development of the orofacial dyskinesias and it is believed the patient's multiple medical problems at the time led to reduced clearance of modafInil which is metabolized by the liver and predominantly excreted in the urine.
Drug-Induced Hyperkinetic Movement Disorders
Given their prevalence, the wealth of potentially offending drug classes, and their potential for reversibility, all hyperkinetic movement disorders should at first be considered iatrogenic until
[An experience of administration of modafinil for excessive daytime sleepiness in a patient with myotonic dystorophy].
The beneficial and adverse effects of modafinil for daytime sleepiness in a 62-year-old female patient with myotonic dystrophy are reported, with partial improvement but aggravation of both dyskinesia and diabetes mellitus.
First Reports of Adverse Drug Reactions
  • International Journal of Pharmaceutical Medicine
  • 2012
Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by Adis Insight. As part of its drug alerting
Monitoring the internet for nootropic substances available to Australian consumers
There is a historical interest in improving cognitive performance for individuals in fields such as academia. Nootropics, also known as smart drugs, are increasingly being used by individuals to


Phenytoin potentiation of neuroleptic‐induced dyskinesias
This animal study suggests that phenytoin may aggravate neuroleptic‐induced tardive dyskinesia through mechanisms other than the dopamine D2 receptors.
Persistent movement disorders induced by buspirone
Two patients with persistent movement disorders that developed after prolonged treatment with buspirone are reported, showing the risk for inducing or exacerbating several types of movement disorders.
Antipsychotic Drug-Induced Movement Disorders
  • P. Blanchet
  • Medicine
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 2003
Among drug-induced movement disorders, antipsychotic drugs and other dopamine receptor blocking agents occupy a central place and their various acute and tardive motor complications provide the template of this short review.
Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study
  • J. Jankovic
  • Psychology, Medicine
    Annals of neurology
  • 1982
Tetrabenazine is a useful and safe therapeutic agent in some patients with hyperkinetic movement disorders and shows marked improvement in one patient with Huntington disease and two patients with congenital choreoathetosis.
A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.
In a 5-year longitudinal study in a cohort of 169 schizophrenic outpatients treated with neuroleptics, we found a twofold increase (from 22% to 44%) in prevalence of tardive dyskinesia (TD) meeting
Acute dyskinesias in young asthmatics treated with theophylline.
An interaction of theophylline, hypoxemia, or other factors related to asthma in the pathophysiology of reversible dyskinesia in two young children, 5 and 30 months of age, is proposed.
Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders
SSRI use appears to be associated with the development of movement disorders, as either a direct result of the drug or exacerbation of an underlying condition, and potential predisposing factors may include the use of neuroleptics, existing neurologic diagnoses, or preexisting movement disorders.
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy
  • Fry
  • Psychology, Medicine
    Annals of neurology
  • 1998
Modafinil demonstrated an excellent safety profile for up to 40 weeks of open‐label treatment and efficacy was maintained, suggesting that tolerance will not develop with long‐term use.
Adrafinil: Effects on behavior and cognition in aged canines
Results indicate that adrafinil is novel behavioral stimulant with cognitive enhancing potential and the underlying mechanisms of action are still unknown.
A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
The presence of TD in lithium-treated patients not treated with neuroleptics for at least 6 months is consistent with the hypothesis that lithium may exacerbate the vulnerability of affective disordered patients to dyskinesias.